Immune-Mediated Hepatitis Induced by Therapy With Alemtuzumab in a Patient With Multiple Sclerosis.
作者信息
Bolte Fabian J, Schmidt Hartmut H-J, Schlevogt Bernhard
机构信息
Department of Internal Medicine B, University Hospital Münster, Münster, Germany.
出版信息
Hepatology. 2021 Jan;73(1):460-463. doi: 10.1002/hep.31435. Epub 2020 Dec 14.
PMID:32583445
Abstract
摘要
相似文献
1
Immune-Mediated Hepatitis Induced by Therapy With Alemtuzumab in a Patient With Multiple Sclerosis.利妥昔单抗治疗多发性硬化症患者所致免疫介导性肝炎
Hepatology. 2021 Jan;73(1):460-463. doi: 10.1002/hep.31435. Epub 2020 Dec 14.
2
Acute severe hepatitis with alemtuzumab and rechallenge after a year.使用阿仑单抗后出现的急性重症肝炎及一年后的再次激发试验
J Clin Neurosci. 2019 Feb;60:158-160. doi: 10.1016/j.jocn.2018.10.055. Epub 2018 Oct 19.
3
Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab.用阿仑单抗治疗的多发性硬化症患者的中性粒细胞减少症
JAMA Neurol. 2017 Sep 1;74(9):1143-1144. doi: 10.1001/jamaneurol.2017.1456.
4
New Warning for the Multiple Sclerosis Drug Alemtuzumab.多发性硬化症药物阿仑单抗的新警告
Am J Nurs. 2019 Mar;119(3):21. doi: 10.1097/01.NAJ.0000554033.89582.5d.
5
Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis.阿仑单抗治疗复发缓解型多发性硬化症后发生的急性后部多灶性鳞状色素上皮病变
J Neurol. 2019 Jun;266(6):1539-1540. doi: 10.1007/s00415-019-09288-y. Epub 2019 Mar 20.
6
Autoimmune storm following alemtuzumab.阿仑单抗治疗后发生的自身免疫风暴。
BMJ Case Rep. 2022 Jun 27;15(6):e248037. doi: 10.1136/bcr-2021-248037.
7
Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.用阿仑单抗治疗复发型多发性硬化症后出现的肿胀性脱髓鞘病变。
Neurology. 2017 Mar 7;88(10):1004-1006. doi: 10.1212/WNL.0000000000003694. Epub 2017 Feb 8.
8
Dominus effect: challenging complications of alemtuzumab-related thyroid autoimmunity.主效应：阿仑单抗相关甲状腺自身免疫的挑战性并发症
J Endocrinol Invest. 2020 Aug;43(8):1159-1161. doi: 10.1007/s40618-020-01204-w. Epub 2020 Mar 4.
9
Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature.阿仑单抗治疗多发性硬化症后早期出现中性粒细胞减少伴血小板减少：病例报告及文献复习
Clin Neurol Neurosurg. 2018 Dec;175:134-136. doi: 10.1016/j.clineuro.2018.11.002. Epub 2018 Nov 3.
10
Alemtuzumab-associated diffuse alveolar damage - a case report.阿仑单抗相关性弥漫性肺泡损伤-1 例报告。
BMC Neurol. 2020 Sep 23;20(1):357. doi: 10.1186/s12883-020-01934-7.
引用本文的文献
1
Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database.基于FAERS数据库的药物性自身免疫性肝炎真实世界药物警戒研究
Sci Rep. 2025 Feb 8;15(1):4783. doi: 10.1038/s41598-025-89272-x.
2
From Multiple Sclerosis to Organ-Specific Autoimmune Disorders: Insights into the Molecular and Clinical Implications of Comorbidity.从多发性硬化症到器官特异性自身免疫性疾病：对共病的分子及临床意义的见解
Mol Neurobiol. 2025 Mar;62(3):3396-3411. doi: 10.1007/s12035-024-04458-0. Epub 2024 Sep 17.
3
Autoimmune liver disease and multiple sclerosis: state of the art and future perspectives.自身免疫性肝病与多发性硬化症：现状与未来展望。
Clin Exp Med. 2023 Nov;23(7):3321-3338. doi: 10.1007/s10238-023-01128-8. Epub 2023 Jul 8.
4
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.《复发缓解型多发性硬化症及其肝损伤的疾病修饰治疗：叙事性综述》。
CNS Drugs. 2021 Aug;35(8):861-880. doi: 10.1007/s40263-021-00842-9. Epub 2021 Jul 28.
Zotero 插件